# Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

> **NCT06033586** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Protagonist Therapeutics, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Open-label rusfertide

## Key facts

- **NCT ID:** NCT06033586
- **Lead sponsor:** Protagonist Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06033586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06033586, "Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06033586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*